Nanomedicines & Translational Drug Delivery group

Página Inicial
Portugal
Porto
Nanomedicines & Translational Drug Delivery group

This is the webpage of Nanomedicines & Translational Drug Delivery group @ i3S Welcome to Bruno Sarmento Research Team facebook!

Our research is based at i3S - Institute of Research and Innovation in Health, University of Porto, Portugal, where we are surrounded by an enthusiastic and well-equipped research environment. Our research is focused on the study of nanomedicines e.g., polymer-based nanoparticles, solid lipid nanoparticles and polymeric micelles, and their application in the pharmaceutical and biomedical fields, a

s well as on the use of in vitro cell models as a tool to correlate the transport of biopharmaceuticals and nanoparticles across human mucosae. The rationale for our research concept stems from the idea of developing valuable and robust nano-based drug delivery systems and economic tissue technology based on simple tissue engineering concepts, to improve the efficacy in drug targeted therapy and, consequently, increasing the effectiveness of drugs with high potential therapeutic outcome.

02/06/2026

Meet our group member Maria João Faria!

Maria João is a Junior Researcher at i3S. She is currently working on anisotropic nanoparticles, mucus transport, diabetes, biopharmaceuticals, oral delivery. You can find more about her work at https://www.i3s.up.pt/personal-info.php?id=6004&idg=109

In her free time, Maria João likes to travel, attend music concerts, go to the cinema, gardening, and spend time with friends.

29/05/2026

Almost closing 3 inspiring days at the European Federation for Pharmaceutical Sciences (EUFEPS) Annual Meeting in beautifull with my invited talk on our work on FcRn-targeted nanoplatforms for oral delivery of biologics. Thanks .Bilensoy for the invitation and organizing the BABP session! https://lnkd.in/eXePJ_Mq

13/05/2026

Did you know that diabetes mellitus affects around 589 million adults worldwide and this number is expected to rise up to 853 million by 2050 if the current trends continue?
Diabetes mellitus remains a major global health challenge, and current treatment strategies often relies on the subcutaneous administration of antidiabetic peptides, as insulin or GLP-1 analogs. While effective, these treatments can be invasive and frequently require multiple doses, which can affect patient adherence.

SUPERATE project is working to change that. Our main goal is to develop mucodiffusive anisotropic nanoparticles for the oral delivery of antidiabetic peptides, improving their oral bioavailability and paving the way for more patient-friendly therapies.
Instituto de Investigação e Inovação em Saúde

04/05/2026

Congratulations to Ana Baião on successfully defending her PhD! Her work on the development of a novel combination therapy for colorectal cancer, combining CD44v6-targeted chemotherapy with immunotherapy, is truly remarkable. Well-done!
Instituto de Investigação e Inovação em Saúde ICBAS - Instituto de Ciências Biomédicas Abel Salazar

26/04/2026

Two recent publications developed through international collaborations, highlighting the growing impact of nanomedicine in addressing complex biomedical challenges. The first study, conducted with the Universidad Complutense de Madrid, presents an innovative approach to improving drug delivery across the blood–brain barrier through post-insertion functionalization of lipid nanocapsules with cannabidiol using click chemistry: https://doi.org/10.1016/j.colsurfb.2026.115736. This work demonstrates how advanced surface engineering of nanocarriers can enhance brain targeting and drug transport to the central nervous system.

The second publication, in collaboration with the University of Chieti–Pescara, explores oxidative cues as theranostic switches for ROS-responsive nanotheranostics in oxidative stress-driven diseases: https://doi.org/10.1016/j.jconrel.2026.114933. It highlights how reactive oxygen species can be used as biological triggers to design smart nanomedicine platforms that integrate diagnosis and therapy.

Together, these studies reinforce the role of nanomedicine in enabling targeted delivery and responsive therapeutic systems, contributing to the advancement of precision medicine.

13/04/2026

I had the privilege and honor of being inducted into the College of Fellows, today, in . This distinction reflects the work of my outstanding research group, whose commitment has enabled advances in bioengineered nanomedicines for targeted drug delivery and the development of biomimetic 3D multicompartmental tissue models for nanomedicine screening. I am deeply grateful for the creativity, rigor, and dedication that my team brings to our shared scientific journey. I look forward to actively advocating for AIMBE and its principles, and to contributing to a community that drives impactful innovation in medical and biological engineering. Congratulations to all the 2026 Class of the AIMBE new Fellows!
https://aimbe.org/press/sarmento-COF-9527.pdf
Instituto de Investigação e Inovação em Saúde CESPU

24/03/2026

These days in actively participating in the 15th WorldMeeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology. This is a valuable opportunity to showcase our work within the project and to explore collaborations around other 3D models we have developed.

https://worldmeeting.org/

13/03/2026

Congratulations to Helena Almeida for brilliantly defend her PhD on engineering anisotropic nanoparticles as carriers for the oral administration of therapeutic peptides. Well-done!
Instituto de Investigação e Inovação em Saúde ICBAS - Instituto de Ciências Biomédicas Abel Salazar

10/03/2026

Latest paper led by Rui Moura, in collaboration with Anne des Rieux, UCLouvain – Université catholique de Louvain now online @ Journal of Controlled Release. In an early treatment protocol, lipid nanocapsules containing retinoic acid significantly reduced disease severity in the experimental autoimmune encephalomyelitis model. Demyelination was attenuated in fluoromyelin-negative area in spinal cord tissue.
These findings highlight the potential of nanocarrier-based delivery of immunomodulatory molecules as an early intervention strategy in neuroinflammatory disease models
https://doi.org/10.1016/j.jconrel.2026.114804

09/03/2026

Meet our group member Isabel Freitas!

Isabel is a PhD Student Instituto de Investigação e Inovação em Saúde & ICBAS - Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto. She is currently working on alendronate-functionalized nanosystems for targeting Osteosarcoma. You can find more about her work at https://www.i3s.up.pt/personal-info.php?id=5821&idg=109

In her free time, Isabel likes to read, crochet and do puzzles.

Endereço

I3S/Rua Alfredo Allen 208
Porto

Website

https://www.i3s.up.pt/research-group.php?groupid=109

Notificações

Seja o primeiro a receber as novidades e deixe-nos enviar-lhe um email quando Nanomedicines & Translational Drug Delivery group publica notícias e promoções. O seu endereço de email não será utilizado para qualquer outro propósito, e pode cancelar a subscrição a qualquer momento.